Drugs that contain Imiquimod
1. Drug name - ALDARA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7696159 | BAUSCH | Treatment for basal cell carcinoma |
Apr, 2024
(1 year, 6 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7696159
(Pediatric) | BAUSCH | Treatment for basal cell carcinoma |
Oct, 2024
(2 years from now) | |
Treatment: NA
Dosage: CREAM;TOPICAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 5% | CREAM;TOPICAL | Prescription |
2. Drug name - ZYCLARA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10238645 | BAUSCH | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts |
Aug, 2029
(6 years from now) | |
| US8598196 | BAUSCH | Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy |
Aug, 2029
(6 years from now) | |
| US8299109 | BAUSCH | Method of treating actinic keratosis with 3.75% imiquimod cream |
Dec, 2029
(7 years from now) | |
| US8236816 | BAUSCH | 2×2×2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75 % imiquimod |
Dec, 2029
(7 years from now) | |
| US8222270 | BAUSCH | 2×2×2 week treatment regimen for treating actinic keratosis with pharmaceutical compositions formulated with 2.5% imiquimod |
Dec, 2029
(7 years from now) | |
| US10238644 | BAUSCH | 2×2×2 week dosing regimen for treating acting keratosis with pharmaceutical compositions formulated with 3.75% imiquimod |
Dec, 2029
(7 years from now) | |
| US10918635 | BAUSCH | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts |
Apr, 2030
(7 years from now) | |
| US11202752 | BAUSCH | Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy |
Apr, 2030
(7 years from now) | |
Treatment: Treatment of genital warts; treatment of perianal warts; Treatment of actinic keratosis; Treatment of perianal warts; treatment of genital warts
Dosage: CREAM;TOPICAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 2.5% | CREAM;TOPICAL | Prescription |
| 3.75% | CREAM;TOPICAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.